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Women with an oestrogen receptor (ER)-positive (+ve) breast cancer have
variable beneﬁt from hormone therapy. The quantitative expression of the ER
and progesterone receptor (PR) has a predictive and prognostic value, but
other molecular variables such as receptor co-activators and peptide growth
factors also play a role. Correlations between these variables have been
described, such as lower levels of steroid receptors in ER+ve breast cancers
overexpressing HER-2/neu. We examined whether PR expression aﬀects
HER-2/neu status in women with an ER+ve breast cancer. Charts from 1567
consecutive women with an operable breast cancer, treated between January
2000 and March 2003 at the University Hospitals Leuven, were retro-
spectively evaluated. We excluded all women who had surgery for recurrent
breast cancer or following neoadjuvant treatment (n=319) and those with an
ER-negative breast cancer (n=246). The correlation between the immunohis-
tochemical (IHC) expression of PR and HER-2/neu was evaluated in all of
the other women. ER, PR and HER-2/neu status was evaluated using IHC.
IHC stains for ER (6F11/2) and PR (312) were semi-quantitatively evaluated
using the H-score and DAKO-score for HER-2/neu.
Our study population included 1002 patients with an ER-positive tumour. PR
was absent and HER-2/neu was overexpressed in 22.5% and 13.9% of cases,
respectively. 21.3% of 777 ER+ve/PR-negative breast cancers overexpressed
HER-2/neu, while this ﬁgure was 11.7% for 225 ER+ve/PR+ve breast cancers
(P < 0.001). In multivariate analysis, taking other tumour predictors for HER-2/
neu status into account, an absent PR (P<0.001) together with a high tumour
grade (P < 0.001) were both predictive for HER-2/neu overexpression in ER+ve
breast cancer. The results show that an absent PR is an independent predictor of
HER-2/neu overexpression for patients with an ER+ve breast cancer. Whether
women with an ER+ve/PR-negative breast cancer need more aggressive therapy
or a combination of hormone therapy and HER-2/neu antibodies than to women
with ER+ve/PR+ve breast cancers will become apparent from the results of large
breast cancer treatment trials taking all of these diﬀerent variables into
consideration.
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